The risk of HIV, HBV, HCV and HTLV infection among musculoskeletal tissue donors in Australia

American Journal of Transplantation

Volumn 7, Issue 12, 2007, Pages 2723-2726

  Yao, F ^a   Seed, C ^a,b   Farrugia, A ^c   Morgan, D ^d,e   Cordner, S ^f   Wood, D ^a,g   Zheng, M H ^a,g  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b AUSTRALIAN RED CROSS BLOOD SERVICE   (Australia)

^c THERAPEUTIC GOODS ADMINISTRATION   (Australia)

^d UNIVERSITY OF QUEENSLAND   (Australia)

^e Queensland Bone Bank   (Australia)

^f Donor Tissue Bank of Victoria   (Australia)

^g Perth Bone and Tissue Bank Inc   (Australia)

Author keywords

Biomaterials; Bone allotransplantation; Orthopedic surgery; Virus transmission

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN T CELL LEUKEMIA VIRUS ANTIBODY;

ANTIBODY DETECTION; ARTICLE; AUSTRALIA; BLOOD DONOR; BONE TISSUE; CONTROLLED STUDY; DONOR; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN T CELL LEUKEMIA VIRUS; HUMAN T CELL LEUKEMIA VIRUS INFECTION; MAJOR CLINICAL STUDY; MUSCULOSKELETAL SYSTEM; NUCLEIC ACID AMPLIFICATION; PREVALENCE; PRIORITY JOURNAL; PROBABILITY; RISK ASSESSMENT; RISK FACTOR; VIREMIA; VIRUS TRANSMISSION;

ANTIBODIES, VIRAL; AUSTRALIA; DELTARETROVIRUS; DELTARETROVIRUS INFECTIONS; DISEASE TRANSMISSION; DNA, VIRAL; HEPACIVIRUS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HIV; HIV INFECTIONS; HUMANS; MUSCULOSKELETAL SYSTEM; NUCLEIC ACID AMPLIFICATION TECHNIQUES; PREVALENCE; RETROSPECTIVE STUDIES; RISK FACTORS; TISSUE AND ORGAN PROCUREMENT; TISSUE DONORS; TISSUE TRANSPLANTATION;

EID: 35748978801     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2007.02012.x     Document Type: Article

References (21)

1. Transplantation Society of Australia and New Zealand. Bank Activities (2002-2204). Available from : http://www.atbf.org.au, accessed August 2006.
2. Zou S, Dodd RY, Stramer SL, Strong DM. Probability of viremia with HBV, HCV, HIV, and HTLV among tissue donors in the United States. N Engl J Med 2004 351 : 751 759.
3. Seed CR, Kiely P, Keller AJ. Residual risk of transfusion transmitted human immunodeficiency virus, hepatitis B virus, hepatitis C virus and human T lymphotrophic virus. Intern Med J 2005 35 : 592 598.
4. Seed CR, Cheng A, Ismay SL et al. Assessing the accuracy of three viral risk models in predicting the outcome of implementing HIV and HCV NAT donor screening in Australia and the implications for future HBV NAT. Transfusion 2002 42 : 1365 1372.
5. Dodd RY, Notari EP, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion 2002 42 : 975 979.
6. Petersen LR, Satten GA, Dodd R et al. Duration of time from onset of human immunodeficiency virus type 1 infectiousness to development of detectable antibody. The HIV Seroconversion Study Group. Transfusion 1994 34 : 283 289.
7. Tugwell B, Patel P, Williams I. Transmission of hepatitis C virus to several organ and tissue recipients from an antibody-negative donor. Ann Intern Med 2005 143 : 648 654.
8. Glynn SA, Kleinman SH, Wright DJ, Busch MP. International application of the incidence rate/window period model. Transfusion 2002 42 : 966 972.
9. Coste J, Reesink HW, Engelfriet CP et al. Implementation of donor screening for infectious agents transmitted by blood by nucleic acid technology: Update to 2003. Vox Sang 2005 88 : 289 303.
10. Galea G, Dow BC. Comparison of prevalence rates of microbiological markers Between bone/tissue donations and new blood donors in Scotland. Vox Sang 2006 91 : 28 33.
11. Australian Therapeutic Goods Administration. Code of Good Manufacturing Practice - Human Blood and Tissues. Australian Therapeutic Goods Administration, Wooden ACT Australia 2000.
12. Kleinman S, Busch MP, Korelitz JJ, Schreiber GB. The incidence/window period model and its use to assess the risk of transfusion-transmitted human immunodeficiency virus and hepatitis C virus infection. Transfus Med Rev 1997 11 : 155 172.
13. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med 1996 334 : 1685 1690.
14. Jackson BR, Busch MP, Stramer SL, AuBuchon JP. The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations. Transfusion 2003 43 : 721 729.
15. Busch MP, Glynn SA, Stramer SL et al. A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors. Transfusion 2005 45 : 254 264.
16. Busch MP, Lee LL, Satten GA et al. Time course of detection of viral and serologic markers preceding human immunodeficiency virus type 1 seroconversion: Implications for screening of blood and tissue donors. Transfusion 1995 35 : 91 97.
17. Kleinman SH, Busch MP. Assessing the impact of HBV NAT on window period reduction and residual risk. J Clin Virol 2006 36 (Suppl 1) S23 S29.
18. Pillonel J, Saura C, Courouce AM. Prevalence of HIV, HTLV, and hepatitis B and C viruses in blood donors in France, 1992-1996. Transfus Clin Biol 1998 5 : 305 312.
19. Manns A, Wilks RJ, Murphy EL et al. A prospective study of transmission by transfusion of HTLV-I and risk factors associated with seroconversion. Int J Cancer 1992 51 : 886 891.
20. Challine D, Pellegrin B, Bouvier-Alias M, Rigot P, Laperche L, Pawlotsky JM. HIV and hepatitis C virus RNA in seronegative organ and tissue donors. Lancet 2004 364 : 1611 1612.
21. Kleinman S, Stramer S, Mimms L et al. Comparison of preliminary observed yield of HCV and HIV minipool (MP) nucleic acid testing (NAT) with predictions from the Incidence/Window Period (INC/WP) Model. Transfusion 2000 40 : S6 S30.